Dr. D. Beard
DR. D. BEARD is specialist of Nash Pathology
Lanifibranor in NASH: NATiV3, an ongoing phase 3 trial
The New England Journal of Medicine has published the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH. Lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASH...
New targets for NAFLD
NAFLD is a growing cause of chronic liver disease worldwide. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD...
Obese NAFLD children and adolescents: high BMI predicts liver fibrosis
H. Moran-Lev et al. (Dana Dwek Children’s Hospital, Tel Aviv University, Israel) aimed to investigate the predictors for liver fibrosis and the effects of short-term nutritional intervention on steatosis and fibrosis among obese adolescents with NAFLD...
NAFLD and incident chronic kidney disease
The association of NAFLD and CKD has been established before. The aim of this large-scale database study was to investigate the role of NAFLD on emerging CKD, the emergence of end-stage renal disease and the identification of additional risk factors which may increase the risk for CKD in Germany...
Diabetic kidney disease, cardiovascular disease and NAFLD
NAFLD, cardiovascular disease and chronic kidney disease share a common pathophysiology including insulin resistance, oxidative stress, chronic inflammation, dysbiosis and genetic susceptibilities. The aim of this review by C. M. Perdomo et al...
Chronic vitamin C deficiency decreases NAFLD progression
This animal study aimed to reveal the role of vitamin C in NAFLD progression
Read MoreChronic vitamin C deficiency decreases NAFLD progressionMAFLD: brain-gut-liver axis and insulin resistance
There are many complex physio-pathologic connections within the brain, gut, and liver axis. This review by E. Rebelos et al. (University of Turku, Finland) is focused on the early pathophysiology of brain, gut, and liver axis in the context of insulin resistance and specifically addresses two pillars of hepatic insulin resistance....
Read MoreMAFLD: brain-gut-liver axis and insulin resistanceFIB-4 and NFS: which performance?
M. Castellana et al. (National Institute of Gastroenterology "Saverio de Bellis," Research Hospital, Italy) conducted a meta-analysis to assess the performance of the FIB-4 and NFS scores, the 2 most common non-invasive tools, for the appropriate selection of subjects with AF for biopsy. A total of 18 studies evaluating 12,604 subjects were included...
Read MoreFIB-4 and NFS: which performance?Enhanced liver fibrosis test and recognition of liver fibrosis
This retrospective cross-sectional study was conducted among patients recruited from a large, community-based hospital system's outpatient liver clinic from 2001 to 202 in order to determine the performance of the enhanced liver fibrosis (ELF) test as a non-invasive test for assessment of liver fibrosis among patients with NAFLD...
Read MoreEnhanced liver fibrosis test and recognition of liver fibrosisNASH Epidemic: a call to action
NAFLD and NASH are common conditions with a rising burden. As pointed out by F. Kanwal et al. (Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center, Houston,USA), “yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single...
Read MoreNASH Epidemic: a call to actionMAFLD and lipoprotein metabolism
MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidaemia. This review by J. Heeren and L Scheja (University Medical Center Hamburg-Eppendorf, Germany) discusses recent research addressing lipoprotein metabolism in the context of MAFLD...
Identifying patients with high-risk NASH: three ultrasound markers
Identifying patients with high-risk-NASH who are candidates for pharmacologic therapy remains a challenge. K. Sugimoto et al. (Tokyo Medical University, Japan) aimed to develop a score to identify patients with a NAFLD activity score of 4 or greater and clinically significant fibrosis...
Read MoreIdentifying patients with high-risk NASH: three ultrasound markers
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES